Richard J Cassidy1, Pretesh R Patel2, Xinyan Zhang3, Robert H Press2, Jeffrey M Switchenko3, Rathi N Pillai4, Taofeek K Owonikoko4, Suresh S Ramalingam4, Felix G Fernandez5, Seth D Force5, Walter J Curran2, Kristin A Higgins2. 1. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA. Electronic address: richardjcassidy@emory.edu. 2. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA. 3. Department of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA. 4. Department of Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA. 5. Department of Thoracic Surgery, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA.
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) is the standard of care for medically inoperable early-stage non-small-cell lung cancer. Despite the limited number of octogenarians and nonagenarians on trials of SBRT, its use is increasingly being offered in these patients, given the aging cancer population, medical fragility, or patient preference. Our purpose was to investigate the efficacy, safety, and survival of patients ≥ 80 years old treated with definitive lung SBRT. METHODS: Patients who underwent SBRT were reviewed from 2009 to 2015 at 4 academic centers. Patients diagnosed at ≥ 80 years old were included. Kaplan-Meier and multivariate logistic regression and Cox proportional hazard regression analyses were performed. Recursive partitioning analysis was done to determine a subgroup of patients most likely to benefit from therapy. RESULTS: A total of 58 patients were included, with a median age of 84.9 years (range, 80.1-95.2 years), a median follow-up time of 19.9 months (range, 6.9-64.9 months), a median fraction size of 10.0 Gy (range, 7.0-20.0 Gy), and a median number of fractions of 5.0 (range, 3.0-8.0 fractions). On multivariate analysis, higher Karnofsky performance status (KPS) was associated with higher local recurrence-free survival (hazard ratio [HR], 0.92; P < .01), regional recurrence-free survival (HR, 0.94; P < .01), and overall survival (HR, 0.91; P < .01). On recursive partitioning analysis, patients with KPS ≥ 75 had improved 3-year cancer-specific and overall survival (99.4% and 91.9%, respectively) compared with patients with KPS < 75 (47.8% and 23.6%, respectively; P < .01). CONCLUSION: Definitive lung SBRT for early-stage non-small-cell lung cancer was efficacious and safe in patients ≥ 80 years old. Patients with a KPS of ≥ 75 derived the most benefit from therapy.
BACKGROUND: Stereotactic body radiotherapy (SBRT) is the standard of care for medically inoperable early-stage non-small-cell lung cancer. Despite the limited number of octogenarians and nonagenarians on trials of SBRT, its use is increasingly being offered in these patients, given the aging cancer population, medical fragility, or patient preference. Our purpose was to investigate the efficacy, safety, and survival of patients ≥ 80 years old treated with definitive lung SBRT. METHODS:Patients who underwent SBRT were reviewed from 2009 to 2015 at 4 academic centers. Patients diagnosed at ≥ 80 years old were included. Kaplan-Meier and multivariate logistic regression and Cox proportional hazard regression analyses were performed. Recursive partitioning analysis was done to determine a subgroup of patients most likely to benefit from therapy. RESULTS: A total of 58 patients were included, with a median age of 84.9 years (range, 80.1-95.2 years), a median follow-up time of 19.9 months (range, 6.9-64.9 months), a median fraction size of 10.0 Gy (range, 7.0-20.0 Gy), and a median number of fractions of 5.0 (range, 3.0-8.0 fractions). On multivariate analysis, higher Karnofsky performance status (KPS) was associated with higher local recurrence-free survival (hazard ratio [HR], 0.92; P < .01), regional recurrence-free survival (HR, 0.94; P < .01), and overall survival (HR, 0.91; P < .01). On recursive partitioning analysis, patients with KPS ≥ 75 had improved 3-year cancer-specific and overall survival (99.4% and 91.9%, respectively) compared with patients with KPS < 75 (47.8% and 23.6%, respectively; P < .01). CONCLUSION: Definitive lung SBRT for early-stage non-small-cell lung cancer was efficacious and safe in patients ≥ 80 years old. Patients with a KPS of ≥ 75 derived the most benefit from therapy.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Jordan Kharofa; Eric P Cohen; Rade Tomic; Qun Xiang; Elizabeth Gore Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-31 Impact factor: 7.038
Authors: Sameer K Nath; Ajay P Sandhu; Daniel Kim; Anjali Bharne; Polly D Nobiensky; Joshua D Lawson; Mark Fuster; Lyudmila Bazhenova; William Y Song; Arno J Mundt Journal: Radiother Oncol Date: 2011-03-21 Impact factor: 6.280
Authors: Erin E Kent; Rochelle Malinoff; Heather M Rozjabek; Anita Ambs; Steven B Clauser; Marie A Topor; Gigi Yuan; James Burroughs; Anne B Rodgers; Kimberly DeMichele Journal: J Am Geriatr Soc Date: 2016-01 Impact factor: 5.562
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Bryan P Rowe; Daniel J Boffa; Lynn D Wilson; Anthony W Kim; Frank C Detterbeck; Roy H Decker Journal: J Thorac Oncol Date: 2012-09 Impact factor: 15.609
Authors: Robert Timmerman; Lech Papiez; Ronald McGarry; Laura Likes; Colleen DesRosiers; Stephanie Frost; Mark Williams Journal: Chest Date: 2003-11 Impact factor: 9.410
Authors: Ronica H Nanda; Yuan Liu; Theresa W Gillespie; John L Mikell; Suresh S Ramalingam; Felix G Fernandez; Walter J Curran; Joseph Lipscomb; Kristin A Higgins Journal: Cancer Date: 2015-09-08 Impact factor: 6.860
Authors: Mareike K Thompson; Philip Poortmans; Anthony J Chalmers; Corinne Faivre-Finn; Emma Hall; Robert A Huddart; Yolande Lievens; David Sebag-Montefiore; Charlotte E Coles Journal: Br J Cancer Date: 2018-07-31 Impact factor: 7.640